Stoop TF, Javed AA, Oba A, Koerkamp BG, Seufferlein T, Wilmink JW, et al. Pancreatic cancer. Lancet. 2025;405:1182–202.
Hu ZI, O’Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:7–24.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71:209–49.
Tintelnot J, Xu Y, Lesker TR, Schönlein M, Konczalla L, Giannou AD, et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature. 2023;615:168–74.
Gough NR, Xiang X, Mishra L. TGF-β signaling in liver, pancreas, and gastrointestinal diseases and cancer. Gastroenterology. 2021;161:434–52.e15.
Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21:104.
Shi N, Zhang J, Chen SY. DOCK2 promotes asthma development by eliciting airway epithelial-mesenchymal transition. Am J Respir Cell Mol Biol. 2023;69:310–20.
Li Z, Jiao X, Robertson AG, Di Sante G, Ashton AW, DiRocco A, et al. The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses. Oncogene. 2023;42:1857–73.
Song S, Zhang R, Cao W, Fang G, Yu Y, Wan Y, et al. Foxm1 is a critical driver of TGF-β-induced EndMT in endothelial cells through Smad2/3 and binds to the Snail promoter. J Cell Physiol. 2019;234:9052–64.
Chan DW, Hui WW, Wang JJ, Yung MM, Hui LM, Qin Y, et al. DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling. Oncogene. 2017;36:1404–16.
Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu M, et al. Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis. J Clin Investig. 2014;124:564–79.
Yi F, Cai C, Ruan B, Hao M, Yeo SK, Haas M, et al. Regulation of RB1CC1/FIP200 stability and autophagy function by CREBBP-mediated acetylation in an intrinsically disordered region. Autophagy. 2023;19:1662–77.
Ruan B, Wang C, Chen A, Liang J, Niu Z, Zheng Y, et al. Expression profiling identified IL-8 as a regulator of homotypic cell-in-cell formation. BMB Rep. 2018;51:412–7.
Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009;4:1670–80.
Jiang X, Liu J, Wang K, Sun J, Yin H, Jiang Y, et al. ASPM mediates nuclear entrapment of FOXM1 via liquid-liquid phase separation to promote progression of hepatocarcinoma. Genome Biol. 2025;26:68.
Wei T, Zeng C, Li Q, Xiao Z, Zhang L, Zhang Q, et al. FOXM1/DEPDC1 feedback loop promotes hepatocarcinogenesis and represents promising targets for cancer therapy. Cancer Sci. 2024;115:3041–53.
Chen Y, Mao X, Xu Y, Li L, Geng J, Dai T, et al. PTOV1-AS1 desensitizes colorectal cancer cells to 5-FU through depressing miR-149-5p to activate the positive feedback loop with the Wnt/β-catenin pathway. Phytother Res. 2024;38:1313–28.
Bian Y, Xu S, Gao Z, Ding J, Li C, Cui Z, et al. m(6)A modification of lncRNA ABHD11-AS1 promotes colorectal cancer progression and inhibits ferroptosis through TRIM21/IGF2BP2/ FOXM1 positive feedback loop. Cancer Lett. 2024;596:217004.
Nandi I, Smith HW, Sanguin-Gendreau V, Ji L, Pacis A, Papavasiliou V, et al. Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression. J Clin Investig. 2023;133:e162324.
Chesnokov MS, Borhani S, Halasi M, Arbieva Z, Khan I, Gartel AL. FOXM1-AKT positive regulation loop provides venetoclax resistance in AML. Front Oncol. 2021;11:696532.
Kimura H, Sada R, Takada N, Harada A, Doki Y, Eguchi H, et al. The Dickkopf1 and FOXM1 positive feedback loop promotes tumor growth in pancreatic and esophageal cancers. Oncogene. 2021;40:4486–502.
Sun Y, Mu G, Zhang X, Wu Y, Wang S, Wang X, et al. Metabolic modulation of histone acetylation mediated by HMGCL activates the FOXM1/β-catenin pathway in glioblastoma. Neuro-Oncol. 2024;26:653–69.
Wang WD, Shang Y, Wang C, Ni J, Wang AM, Li GJ, et al. c-FLIP promotes drug resistance in non-small-cell lung cancer cells via upregulating FoxM1 expression. Acta pharmacologica Sin. 2022;43:2956–66.
Tong X, Wang S, Lei Z, Li C, Zhang C, Su Z, et al. MYOCD and SMAD3/SMAD4 form a positive feedback loop and drive TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancer. Oncogene. 2020;39:2890–904.
Zhang Y, Yang Y, Qi X, Cui P, Kang Y, Liu H, et al. SLC14A1 and TGF-β signaling: a feedback loop driving EMT and colorectal cancer metachronous liver metastasis. J Exp Clin Cancer Res. 2024;43:208.
Wang M, Ding X, Fang X, Xu J, Chen Y, Qian Y, et al. Circ6834 suppresses non-small cell lung cancer progression by destabilizing ANHAK and regulating miR-873-5p/TXNIP axis. Mol Cancer. 2024;23:128.
Wu MZ, Yuan YC, Huang BY, Chen JX, Li BK, Fang JH, et al. Identification of a TGF-β/SMAD/lnc-UTGF positive feedback loop and its role in hepatoma metastasis. Signal Transduct Target Ther. 2021;6:395.
Stojanovic N, Hassan Z, Wirth M, Wenzel P, Beyer M, Schäfer C, et al. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Oncogene. 2017;36:1804–15.
Degtjarik O, Golovenko D, Diskin-Posner Y, Abrahmsén L, Rozenberg H, Shakked Z. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Nat Commun. 2021;12:7057.
Maki R, Iwagami Y, Kobayashi S, Sasaki K, Yamada D, Tomimaru Y, et al. Efficacy of SOAT1 inhibitors against pancreatic cancer with TP53 mutations. Ann Surg Oncol. 2025;32:7025–37.
